Source:http://linkedlifedata.com/resource/pubmed/id/14962717
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-2-13
|
| pubmed:abstractText |
Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22-49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade > or =3 vomiting, 13%) and haematological (grade > or =3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0959-8049
|
| pubmed:author |
pubmed-author:BaudinEE,
pubmed-author:BoigeVV,
pubmed-author:DelaunoitThT,
pubmed-author:DromainCC,
pubmed-author:DucreuxMM,
pubmed-author:DuvillardPP,
pubmed-author:EliasDD,
pubmed-author:LasserPP,
pubmed-author:RougierPP,
pubmed-author:RuffiePP,
pubmed-author:SabourinJ-CJC,
pubmed-author:SchlumbergerMM,
pubmed-author:de BaereTT
|
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
515-20
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:14962717-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14962717-Doxorubicin,
pubmed-meshheading:14962717-Female,
pubmed-meshheading:14962717-Follow-Up Studies,
pubmed-meshheading:14962717-Humans,
pubmed-meshheading:14962717-Male,
pubmed-meshheading:14962717-Middle Aged,
pubmed-meshheading:14962717-Pancreatic Neoplasms,
pubmed-meshheading:14962717-Streptozocin,
pubmed-meshheading:14962717-Survival Analysis,
pubmed-meshheading:14962717-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?
|
| pubmed:affiliation |
Department of Gastroenterology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
|
| pubmed:publicationType |
Journal Article
|